Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients

• Published in: Seminars in arthritis and rheumatism Vol. 47; no. 2; pp. 288 - 294
• Main Authors: Jamilloux, Yvan, Cohen-Aubart, Fleur, Chapelon-Abric, Catherine, Maucort-Boulch, Delphine, Marquet, Alicia, Pérard, Laurent, Bouillet, Laurence, Deroux, Alban, Abad, Sébastien, Bielefeld, Philip, Bouvry, Diane, André, Marc, Noel, Nicolas, Bienvenu, Boris, Proux, Alice, Vukusic, Sandra, Bodaghi, Bahram, Sarrot-Reynauld, Françoise, Iwaz, Jean, Amoura, Zahir, Broussolle, Christiane, Cacoub, Patrice, Saadoun, David, Valeyre, Dominique, Sève, Pascal
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2017
• Subjects: Adolescent; Adult; Aged; Efficacy; Female; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Infliximab - adverse effects; Infliximab - therapeutic use; Male; Middle Aged; Retrospective Studies; Rheumatology; Safety; Sarcoidosis; Sarcoidosis - drug therapy; TNF antagonist; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Young Adult; OR; Sarcoidosis; CI; MMF; AZA; CNS; WASOG; Efficacy; IQR; CYC; LEF; TNF; AEs; CS; MTX; ePOST; Cy; CZP; IFX; Safety; TNF antagonist; ADA; ETN; leflunomide; certolizumab pegol; Extrapulmonary Physician Organ Severity Tool; infliximab; methotrexate; interquartile range; odds ratio; World Association of Sarcoidosis and Other Granulomatous diseases; adalimumab; corticosteroids; cyclophosphamide; cyclosporine; etanercept; azathioprine; adverse events; central nervous system; tumor necrosis factor; confidence interval; mycophenolate mofetil
• ISSN: 0049-0172; 1532-866X; 1532-866X
• DOI: 10.1016/j.semarthrit.2017.03.005

The off-label use of TNF antagonists in refractory sarcoidosis is increasingly reported but data on their efficacy and safety are still insufficient. To report on efficacy and safety of TNF antagonists in severe and refractory sarcoidosis. Examination of retrospective demographic, clinical, therapeutic, and adverse event data on 132 sarcoidosis patients (58% women; mean (min–max) age = 45.5 (14–78) years) given TNF antagonists (mainly infliximab, 91%) and investigation of response-linked factors. The overall clinical response (complete and partial) rate was 64%. TNF-antagonist efficacy (i.e., significant decrease of the ePOST score) was noted in cases with neurologic, heart, skin, and upper respiratory tract involvements. No significant difference in efficacy was found between anti-TNF used alone and TNF with immunosuppressant. The use of anti-TNF allowed reducing prednisone dosage at end of follow-up (p < 0.001). Adverse events were observed in 52% of the patients; they included infections (36%) and allergic reactions (8%) and required treatment interruption in 31 cases (23%). When TNF antagonists were interrupted, 13 patients experienced relapses within 14 months on average (median follow-up: 20.5 months). TNF antagonists were efficacious in about two-thirds of patients with severe/refractory sarcoidosis but their use led to a high rate of adverse events.